Introduction
Human mammary gland development is marked by significant postnatal changes in response to hormonal signals. At puberty, mammary epithelial cells (MECs) form a system of ducts and branches that penetrate the fatty stroma. Proliferation accompanied by lobuloalveolar growth and differentiation increases during pregnancy. Upon parturition, lactation occurs and the newly formed secretory epithelial cells synthesize and secrete milk. Lastly, involution is triggered and the complex alveolar compartment is remodelled to resemble a virgin-like state.
It is the general consensus among mammary gland biologists that breast tumors arise from perturbations in the normal regulatory pathways that signal these developmental transitions. For instance, the mammary glands of transgenic mice with targeted deletions of the cyclin D1 gene, a critical regulator of the G1 to S cell cycle transition, show severe developmental abnormalities (Fantl et al., 1995 (Fantl et al., , 1999 Sicinski et al., 1995) . Despite normal hormonal cues, the mammary glands do not proliferate during pregnancy and cyclin D1 null animals fail to lactate at parturition. In addition, the progeny of cyclin D1 null animals crossbred with other mouse models of mammary tumorigenesis fail to develop mammary tumors (Yu et al., 2001) . In contrast, mice engineered to assess the effect of targeted cyclin D1 overexpression develop a high incidence of mammary hyperplasia and carcinomas (Wang et al., 1994) . Data compiled from human breast tumor analyses provide further evidence for cyclin D1's oncogenic potential. Between 60 and 80% of all well differentiated and lobular-types of invasive mammary carcinomas are associated with cyclin D1 overexpression (Buckley et al., 1993; Bartkova et al., 1994) .
Gene deletion studies have also identified C/EBPb, a basic-leucine zipper transcription factor, as a key regulator of epithelial cell growth and differentiation in the mammary gland (Robinson et al., 1998; and Seagroves et al., 1998) . The mammary gland phenotype of C/EBPb-null mice is more extensive than that observed in cyclin D1 knockout animals: the mammary epithelial cells (MECs) fail to proliferate in response to hormonal signals at puberty and during pregnancy, and the MECs fail to differentiate in response to lactationspecific hormones. Owing to alternative translation initiation at three in-frame methionines, the intronless C/EBPb gene (also termed NF-IL6 or CEBPB in humans and LAP or Cebpb in rodents) can generate three different protein products (Descombes and Schibler, 1991; Timchenko et al., 1999; Baer and Johnson, 2000; Calkhoven et al., 2000; and Xiong et al., 2001) . The larger isoforms (termed LAP* and LAP in rodents) are transactivators. The smallest isoform (termed LIP in rodents) lacks a transactivation domain and inhibits transcription. Since there are no established terms to differentiate between the various human protein isoforms, we refer to them as C/EBPb -1, -2, and -3 (in descending order according to size) in these studies.
The production of multiple isoforms of C/EBPb (p55, p45/42 doublet, and p20 in humans (Eaton et al., 2001) ; and p42, p38/35 doublet, and p20 in rodents (Calkhoven et al., 2000) ) in cells may explain how a single transcription factor can exhibit contrasting influences on both differentiation and proliferation. Although C/EBPb-1 and -2 differ by only 23 amino acids in humans (21 amino acids in rodents), our laboratory and others have observed functional differences between these two activating isoforms. Kowenz-Leutz and Leutz (1999) reported that only the largest C/EBPb isoform is able to cooperate with Myb to activate the mim-1 gene and other myeloid-specific genes in chromatin. They demonstrated that C/EBPb-1 (termed LAP* in their work) interacts with the SWI/SNF chromatin remodelling complex, whereas C/EBPb-2 (LAP) does not. Interestingly, the N-terminal 21 amino acids of LAP* were shown to be essential, although not sufficient, for recruitment of the SWI/SNF complex (Kowenz-Leutz and Leutz, 1999) . We have previously observed a striking difference in the expression profiles of C/EBPb-1 and -2 in normal versus neoplastic human mammary epithelial cells derived from both primary tissues and established cell lines (Eaton et al., 2001) . Specifically, 12 normal breast tissue samples from reduction mammaplasties exclusively expressed C/EBPb-1, whereas seven of 10 surgical primary breast tumor samples acquired C/EBPb-2. C/EBPb-1 is completely absent from breast cancer cell lines in culture. We also demonstrated that these distinct expression profiles have functional significance: the cyclin D1 promoter (which contains C/EBPb consensus-binding sites) was activated by C/EBPb-2, but slightly repressed by C/EBPb-1 in transient transfection assays. Taken together, these data suggest that the two C/EBPb activator isoforms carry out distinct roles in MECs, with C/EBPb-1 regulating transcription of genes in nonproliferating or differentiating MECs, and C/EBPb-2 promoting growth. We have begun to test this possibility by selectively expressing C/EBPb-2 in normal human MECs.
Using recombinant retroviral technology, we have engineered MCF10A cells, a normal human MEC line, to selectively overexpress epitope-tagged C/EBPb-2 alone, or along with a marker, green fluorescent protein (GFP). We demonstrate that elevated levels of tagged C/EBPb-2 are achieved and correlate with the acquisition of transformed characteristics including loss of contact inhibition, decreased anchorage dependence, altered protein expression patterns associated with epithelial-to-mesenchymal transition (EMT), and gain of an invasive phenotype. While C/EBPb is involved in the regulation of numerous genes, one interesting target is cyclooxygenase-2 (COX-2). Increased levels of COX-2 have been implicated in mammary tumorigenesis Half et al., 2002) . The COX-2 gene promoter contains a C/EBP element and C/EBPb is required for COX-2 expression in some cell types (Kim and Fischer, 1998; Reddy et al., 2000; Thomas et al., 2000; Wadleigh et al., 2000; Yuan et al., 2000; Caivano et al., 2001; Gorgoni et al., 2001; Wardlaw et al., 2002) . We show that COX-2 levels are elevated in C/EBPb-2-overexpressing, but not C/EBPb-1-overexpressing, MCF10A cells. Thus, COX-2 may be one of the targets by which sustained aberrant expression of C/EBPb-2 in normal MECs contributes to deregulated proliferation and promotes metastatic transformation in culture.
Results
Overexpression of C/EBPb-2 in MCF10A cells MCF10A cells were modified to overexpress C/EBPb-2 by infecting with recombinant retrovirus encoding T7 epitope-tagged rat C/EBPb-2. We used epitope-tagged protein in order to unequivocally distinguish exogenous C/EBPb-2 from the endogenous C/EBPb proteins present in MCF10A cells. Previously, we have used both tagged and nontagged C/EBPb proteins and have not observed any functional differences imparted by the small T7 epitope tag. For example, both tagged and untagged C/EBPb-2 bind to the serum response factor and Ets family member, Elk-1, in response to activated Ras in vivo (Hanlon et al., 2000) . Two versions of recombinant tagged-C/EBPb-2 retrovirus were generated: LZRS-His-C/EBPb-2 and LZRS-His-C/EBPb-2-IRES-GFP, as illustrated in Figure 1 . Figure 1 Diagram of LZRS-based recombinant retroviral constructs. The previously described EBV/retroviral hybrid vector, pLZRS-LacZ, was used to generate b-galactosidase (Lac-Z) recombinant retrovirus (Kinsella and Nolan, 1996) . The backbone of this vector was also used to generate three additional recombinant retroviral constructs. The general features of each recombinant provirus generated is shown: the original LZRS-Lac-Z provirus (a), the LZRS-His-C/EBPb-2 provirus (b) that encodes epitope-tagged C/EBPb-2, the LZRS-IRES-GFP provirus (c) that encodes the marker GFP downstream of an IRES, and the LZRSHis-C/EBPb-2-IRES-GFP provirus (d) that encodes both epitopetagged C/EBPb-2 and GFP from a single bicistronic message. Each recombinant provirus contains identical long terminal repeat (LTR) and psi packaging sequences (c) provided by the original pLZRS-Lac-Z construct C/EBPb-2 induces anchorage independence and EMT
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To generate the latter, the IRES and enhanced GFP coding sequences derived from Clontech's pIRES2-EGFP expression vector were inserted downstream of the tagged-C/EBPb-2 sequences. This modification allows for the expression of both tagged-C/EBPb-2 and GFP proteins from a single bicistronic message. Thus, targeted cells can be directly visualized on a fluorescent microscope without additional treatment. The fluorescence intensity of targeted cells can also be used to gauge the relative expression level of tagged-C/EBPb-2. As a control, MCF10A cultures were infected with recombinant retrovirus derived from the previously described vector, pLZRS-LacZ (encoding b-galactosidase, Kinsella and Nolan, 1996) or pLZRS-IRES-GFP (encoding GFP only), also illustrated in Figure 1 .
To verify that tagged-C/EBPb-2 was overexpressed and localized in the nucleus of targeted cells, indirect immunocytochemistry was carried out. The representative confocal images provided in Figure 2 were obtained from MCF10A cells that had been infected with recombinant LZRS-His-C/EBPb-2 only virus. In Figure 2a , the green staining indicates tagged-C/EBPb-2 expression and is observed in both the cytoplasm and nucleus of targeted cells, similar to endogenous C/EBPb-2 (Eaton et al., 2001) . Cells were also stained with the nuclear-specific BO-PRO-3 dye. Thus, the red staining pattern shown in Figure 2b demarcates the nucleus from the rest of the cell. The overlay image provided in Figure 2c demonstrates that tagged-C/EBPb-2 is present in the nucleus of many infected MCF10As, indicated by the yellow color that is C/EBPb-2 induces anchorage independence and EMT LM Bundy and L Sealy produced when the green and red images are superimposed. Uninfected MCF10A cells were treated in parallel to the tagged-C/EBPb-2 targeted cells and no detectable background staining by the T7-tag and secondary Alexa 488 antibodies (Abs) were observed (data not shown). Background staining was also absent in MCF10As infected with the LZRS-LacZ virus, as observed by epifluorescent microscopy (data not shown).
It is important to note that C/EBPb-3 cannot be translated from our C/EBPb-2 construct. This is because alternative translation of the C/EBPb mRNA to produce C/EBPb-3 depends upon a small (9 aa) outof-phase open reading frame (ORF) sandwiched between the first and second in-frame ATGs that initiate translation of C/EBPb-1 and -2, respectively. By deleting amino acids up to the second in-frame ATG, as is the case in our C/EBPb-2-specific expression vector, the small 9 aa out-of-phase ORF is also deleted (Sears and Sealy, 1994) . Thus, alternative translation of the C/EBPb-2 specific expression vector cannot occur (Calkhoven et al., 2000 and Xiong et al., 2001) . However, to demonstrate that expression of tagged-C/EBPb-2 in transduced cells did not result in elevated C/EBPb-3 levels via proteolytic cleavage (Baer and Johnson, 2000) , Western analysis of whole cell lysates (WCLs) from untreated, LZRS-LacZ, or LZRS-His-C/EBPb-2-infected MCF10A cultures was performed (Figure 2d ). The arrows in Figure 2d indicate the locations of the exogenous C/EBPb-2 bands detected in lane 3 containing LZRS-His-C/EBPb-2-infected MCF10A WCL. The identity of these bands was verified by performing additional Western analyses with the anti-T7 epitope tag Ab (data not shown). The endogenous C/EBPb-3 band was detected at approximately 20 kDa in all lanes. While there appears to be a very slight increase in C/EBPb-3 band intensity detected in lane 3 compared to lanes 1 and 2, it is obvious that expression of exogenous tagged-C/EBPb-2 far exceeds that of the C/EBPb-3 detected in lane 3. Bands that correspond to the endogenous, slightly larger human C/EBPb-2 protein, which is detected as a doublet (presumably because of differential phosphorylation), were also observed in each lane. The upper endogenous C/EBPb-2 bands (marked by double asterisks) were detected at equivalent intensities in all lanes, providing verification that equivalent amounts of total protein were loaded in each lane. Detection of the lower endogenous C/EBPb-2 band (marked by a single asterisk) is obscured in lane 3 by the exogenous C/EBPb-2 band of nearly identical mobility.
C/EBPb-2-overexpressing MCF10A cells form foci and gain anchorage-independent growth characteristics MCF10A cells acquire transformed growth properties following infection with either LZRS-His-C/EBPb-2, or LZRS-His-C/EBPb-2-IRES-GFP virus, as illustrated in Figure 3 . Within 2-3 days postinfection, multiple foci begin to form in the MCF10A cultures transduced by either recombinant C/EBPb-2 retrovirus. The representative epifluorescent image shown in Figure 3a was taken 2 days after treating MCF10 cells with LZRS-His-C/EBPb-2-IRES-GFP virus. The cells that express high levels of exogenous C/EBPb-2 (as gauged by their fluorescent intensity) appear to have lost contact inhibition and form aggregated clusters. If provided fresh growth media every 3 days, the foci continue to expand. Two representative foci that had been allowed to grow for 12 days after treatment with LZRS-His-C/EBPb-2 virus are shown in Figure 3b , c. When viewed by phase-contrast microscopy, the cells are readily identified as rounded and refractile. Since the foci are observed soon after retroviral treatment at a significant frequency (a single 60 mm dish contains 50-70 individual foci when infected at an MOI of 100), it is unlikely that this phenotype can be attributed to activation of a cellular gene(s) by retroviral insertion rather than elevated expression of C/EBPb-2. No alterations in morphology or growth characteristics were observed in control MCF10A cultures infected at equivalent MOIs with either LZRS-LacZ or LZRS-IRES-GFP retrovirus (data not shown).
Viable, nonadherent cells began to accumulate in C/EBPb-2-overexpressing cultures within 4 days postinfection if provided fresh media. Based on microscopic observations, the floating cells appear to bud from the foci. Moreover, when cultures infected with LZRS-His-C/EBPb-2-IRES-GFP virus were observed by epifluorescent microscopy, every floating cell expressed GFP. The nonadherent cells were subcultured as described in 'Material and methods'. Following their addition to new cultureware, the cells adhere and repopulate the dish. Interestingly, nonadherent cells accumulate again once the cells reach approximately 70% confluence (when provided fresh growth media). The representative photomicrograph of confluent, untreated MCF10A cells shown in Figure 3d contrasts the phenotype observed in three representative images of independently infected and isolated, floating subcultures resulting from ectopic overexpression of tagged C/EBPb-2 provided in Figure 3e , f, and g, respectively. The floating subcultures were derived from cultures containing numerous foci (approximately 60) generated by replication-deficient recombinant virus. Thus, the subcultures are nonclonal populations of C/EBPb-2-overexpressing cells. Nontransformed mammary epithelial cells require adhesion for viability in culture. The floating subcultures have undergone changes that enable them to override this requirement. Since C/EBPb-2 overexpression is required for this phenotype, we hypothesize that C/EBPb-2 is participating in the pathway(s) that lead to this nonadherent growth behavior.
C/EBPb-2-overexpressing MCF10A cells grow in soft agar
Given the reduced adhesion requirements demonstrated by the C/EBPb-2-overexpressing MCF10A cells when grown on plastic substrata, we determined their ability to form colonies in soft agar. Uninfected MCF10A cells, or MCF10A cells, collected 1 week after infection with tagged-C/EBPb-2 virus, were resuspended in agar. The breast cancer cell line MDA-MB-231 was also employed as a positive control. Representative photomicrographs of the colonies formed after 20 days in soft agar are provided in Figure 4 . The colonies observed in the MCF10A cells targeted to overexpress tagged-C/EBPb-2 were predominantly larger than the colonies generated by the positive control MDA-MB-231 breast cancer cell line. However, colonies were more numerous in the tumor cell line. The average colony number per dish was 400 for MDA-MB-231 cells and 90 for the MCF10A cells overexpressing tagged-C/EBPb-2. No colonies were observed in the dishes that contained uninfected MCF10A cells.
C/EBPb-2-overexpressing MCF10A cells show altered protein expression patterns consistent with having undergone EMT Normal MECs form E-cadherin-mediated adherens junctions. In contrast, breast carcinomas that have undergone an epithelial to mesenchymal transition exhibit alterations in both cell-cell and cell-extracellular matrix (ECM) interactions (Gilles and Thompson, 1996) . Specifically, the organization of E-cadherin at the adherens junctions is disrupted and junctional localization of this protein becomes discontinuous or absent. We therefore characterized the cellular staining pattern of E-cadherin in tagged-C/EBPb-2-overexpressing MCF10A floating subcultures. As shown in Figure 5b , MCF10A cells infected with LZRS-IRES-GFP virus showed a clear organization of E-cadherin staining at cellular junctions. In contrast, a loss of E-cadherin junctional localization was observed in the C/EBPb-2-overexpressing cells shown in Figure 5d . In the C/EBPb-2-overexpressing cells, E-cadherin expression was concentrated in the nucleus with diffuse staining also observed in the cytoplasm. This staining pattern was consistently observed in all the tagged-C/EBPb-2-overexpressing subcultures analysed (data not shown).
Figure 3 C/EBPb-2-infected MCF10As form foci and gain anchorage-independent growth properties when grown on plastic substrata. Foci were detected by epifluorescence 2 days postinfection of MCF10A cells with LZRS-His-C/EBPb-2-IRES-GFP virus (a). Bar, 20 mm. Photomicrographs of representative foci observed in MCF10A cultures allowed to grow 12 days after infection with LZRS-His-C/EBPb-2 (b and c). Bar, 100 mm. Floating subcultures were established from nonadherent cells in C/EBPb-2-overexpressing cultures, as described in 'Materials and methods'. Photomicrographs of an untreated MCF10A culture (d) and three independent C/EBPb-2-overexpressing subcultures, 3900-6F (e), 1214F (f), and 0129F (g). Bar,100 mm C/EBPb-2 induces anchorage independence and EMT LM Bundy and L Sealy Another characteristic of cells that have undergone EMT is the acquisition of a spindle-shape morphology, which is associated with increased cellular motility and cytoskeletal reorganization into actin stress fibers (Gilles and Thompson, 1996) . Fluorescent-conjugated phalloidin staining of untreated MCF10A cells and LZRS-IRES-GFP-infected MCF10As showed notable staining at regions of cellular contact, typical of sheets of cultured MECs (Figure 6 , panels a and b, respectively). The contrasting morphology of two similarly stained C/EBPb-2-overexpressing subcultures (O129F and 501F) is illustrated in Figure 6 , panels c and d, respectively. The elongated, ruffled staining pattern typical of motile fibroblasts is observed along the edges of the C/EBPb-2-overexpressing cells. Also, actin stress fibers are readily detected, providing confirmation of cytoskeletal reorganization.
The expression of vimentin, an intermediate filament, is the hallmark feature of breast tumor cells that have undergone EMT (Sommers et al., 1989 Thompson et al., 1992; Lochter et al., 1997a) . As neoplastic epithelial cells progress toward invasive growth they often express vimentin. Therefore, we performed indirect immunocytochemistry on untreated MCF-10As, a C/EBPb-2-overexpressing MCF10A subculture, 3900-6F, and MDA-MB-231s, a breast cancer cell line known to express vimentin . As shown in Figure 7a , untreated MCF10A cells do not express vimentin, consistent with their epithelial phenotype, while vimentin expression is clearly detectable in the MDA-MB-231 cells ( Figure 7b ). As demonstrated in Figure 7c , vimentin expression was also readily detected in the C/EBPb-2-overexpressing subculture. No background staining by the fluorescent-conjugated secondary Ab alone was observed in any of the cells shown in Figure 7 (data not shown). Thus, we conclude that ectopic expression of C/EBPb-2 in MCF10A cells is sufficient to induce EMT, as manifested by vimentin expression, spindle-shape morphology, and E-cadherin delocalization.
MCF10A-C/EBPb-2-overexpressing cells are invasive
EMT has been associated with an invasive phenotype in human breast tumor cell lines ). Thus, we tested whether C/EBPb-2 overexpression would cause MCF10A cells to acquire invasive properties as measured by in vitro basement membrane invasion assays. In these studies, cells must degrade a uniform barrier of Matrigel, reconstituted basement membrane prepared from Englebreth-Holm-Swarm (EHS) tumor, and traverse a porous filter in response to a chemotactic gradient. As shown in Figure 8a , C/EBPb-2 overexpression confers upon MCF10A cells the ability to degrade the Matrigel and penetrate through the porous filters similar to the well-characterized, highly invasive MDA-MB-231 human breast tumor line. In contrast, untreated MCF10A cells are Figure 8a were taken from one of several independent studies performed. The results of three independent studies that included untreated MCF10A and MDA-MB-231 cells (negative and positive controls, respectively), as well as MCF10A cultures infected with GFP virus or C/EBPb-2 virus, were quantified and presented graphically in Figure 8b . Invasive activity was normalized to that of the MDA-MB-231 cells included in each assay, which consistently score highest among human breast cancer cells in chemoinvasion assays (Zajchowski et al., 2001) . The C/EBPb-2-overexpressing MCF10A subculture (0129F) demonstrated an invasive activity 69% (s.e.m. 7 6.5%) that of the MDA-MB-231 cell line. Although only the activity of one C/EBPb-2-overexpressing subculture (0129F) was reported in Figure 8b , a total of three independent C/EBPb-2-overexpressing subcultures were analysed in these assays. The two other C/EBPb-2-overexpressing subcultures scored similarly to that of the 0129F subculture, with invasive scores ranging from 100 to 64% of the MDA-MB-231 activity. However, they were not included in all three independent assays. In addition, untreated MCF10A cells and LZRS-IRES-GFP-infected MCF10A cells were also included in each assay. The difference between the relative invasive potential of untreated MCF10A and GFP-infected MCF10A cultures was small (4.4%), and determined to be statistically insignificant. In contrast, the difference between the relative invasive potential of the C/EBPb-2-overexpressing MCF10A subculture (0129F) and that of untreated and GFP-overexpressing MCF10A cells was much larger (60.5 and 56.1%, respectively) and statistically significant (P-value o0.001).
COX-2 expression is elevated in C/EBPb-2-, but not C/EBPb-1-, overexpressing MCF10A cells
It is obvious that the nuclear form of C/EBPb-2 could be directly or indirectly involved in many changes in gene regulation that lead to cellular transformation (Hay, 1995; Gilles and Thompson, 1996; Danen and Yamada, 2001) . As one example, COX-2 is an inducible prostaglandin synthase whose expression can induce mammary tumorigenesis in transgenic mice ).
COX-2 is frequently overexpressed in invasive breast cancers and in adjacent DCIS and, thus, may be an early event in mammary tumorigenesis (Half et al., 2002) . The COX-2 gene promoter contains a C/EBP clonal, but are randomly infected cells that have been selected for their transformed character (i.e. anchorage-independent growth) and both showed a higher level of COX-2 expression than the randomly C/EBPb-2-infected population (lane 3). In contrast, MCF10A cells randomly infected with His-C/EBPb-1 virus showed no COX-2 expression (lane 4). The His-C/EBPb-1 virus was recently generated in our lab using the LZRS-IRES-GFP vector described previously (Figure 1 ) except that epitope-tagged C/EBPb-1 is exclusively expressed from the bicistronic viral mRNA along with GFP. For selective expression of C/EBPb-1, a perfect Kozak sequence was created around the first ATG and the second in-frame methionine in the C/EBPB gene was mutated to valine by site-directed mutagenesis techniques. The cultures corresponding to lanes 2 (GFP overexpressing), 3 (C/EBPb-2 overexpressing), and 4 (C/EBPb-1 and GFP overexpressing) were infected under identical conditions and each was comprised of a small population (3-5%) of uninfected as well as a random population of infected cells (that included a range of ectopic expression levels). The relative levels of exogenous C/EBPb protein were determined by performing additional Western analysis with the anti-T7 tag Ab (Figure 9b ). The level of exogenous C/EBPb-1 protein (Figure 9b lane 1) was actually higher than exogenous C/EBPb-2 expression (Figure 9b lane 2) in the randomly infected population, and comparable to that observed in the C/EBPb-2-overexpressing 9100F subculture (Figure 9b , lane 3).
Discussion
The studies presented here demonstrated that C/EBPb-2 overexpression results in oncogenic transformation of human MCF10A mammary epithelial cells in culture. The immortalized, but nontransformed cells assume characteristics of invasive, metastatic breast cancer cells that have undergone EMT, including anchorageindependent growth in soft agar, lack of cell-cell adhesion, delocalization of E-cadherin expression to the nucleus, acquisition of actin stress fibers and the mesenchymal intermediate filament protein, vimentin, and the ability to invade through a basement membrane (matrigel) in culture. The oncogenic activity of this isoform of C/EBPb may be somewhat surprising, given that C/EBPb is a transcription factor whose role in the activation of differentiation-specific genes in hepatocytes, adipocytes, and macrophages has been well characterized. However, Zhu et al. (2002) have recently reported that C/EBPb is an essential mediator of skin tumorigenesis involving oncogenic Ras signalling. C/EBPb-null mice are completely refractory to carcinogen-induced skin tumors involving mutant Ras. Additionally, C/EBPb-null hepatocytes fail to respond to transforming growth factor alpha (TGFa), and posthepatectomy DNA synthesis is decreased to 25% of normal in C/EBPb-null mice (Buck et al., 1999) . Buck et al. (2001) have also shown that phosphorylation of C/EBPb on mouse/human threonine 217 or rat serine 105 by TGFa-activated ribosomal protein S-6 kinase (p90-RSK) is required for the proliferative response of primary mouse hepatocytes to TGFa. We propose that the production of two transactivator proteins (b-1 and -2) from the same C/EBPb mRNA is one mechanism by which this transcription factor can exhibit contrasting influences on both differentiation and proliferation. C/EBPb-1 is uniquely situated to activate differentiation-specific gene transcription because of its ability to interact with chromatin remodelling complexes such as SWI/SNF, whereas C/EBPb-2 cannot (Kowenz-Leutz and Leutz, 1999) . However, in many instances terminal differentiation is preceded by a period of cellular proliferation. Thus, we propose that the C/EBPb gene encodes a second transactivator, embedded within the coding sequences of the first, whose function is to promote cellular proliferation, motility, and invasion, prior to differentiation. Therefore, disrupting the balance of C/EBPb-1 versus -2 expression in cells may contribute to neoplastic transformation.
Other investigators (Raught et al., 1996 , Zahnow et al., 1997 , 2001 have proposed that C/EBPb-3 (LIP) expression is oncogenic. Our studies here do not directly address this possibility, except to suggest that the consequences of C/EBPb-3 expression may vary, depending on which of the longer isoforms, C/EBPb-1 or, -2, is predominantly expressed. For example, C/EBPb-1 is the only isoform expressed in normal human mammary tissue from reduction mammaplasty (Eaton et al., 2001) . Introducing C/EBPb-3 expression into normal cells that express predominantly C/EBPb-1 would be expected to inhibit or block terminal differentiation. However, in cells where C/EBPb-2 is the only or predominant transactivator isoform, C/EBPb-3 overexpression may antagonize growth and invasion. Indeed, Hirai et al. (2001) found that moderate levels of LIP expression in SCp2 mouse mammary epithelial cells, which express LAP (C/EBPb-2), promoted luminal morphogenesis, whereas high expression of LIP led to apoptosis. With regard to human breast tumor tissue, Zahnow et al. (1997) reported that highgrade, invasive human mammary carcinomas exhibit high levels of LIP (p20) or C/EBPb-3 expression. In previous studies, we did not observe elevated C/EBPb-3 (LIP) expression in any of the human breast tumor samples examined, although seven of the 10 tumors examined were high-grade, invasive mammary carcinomas (Eaton et al. 2001) . Since C/EBPb-3 is easily generated by artifactual proteolysis during extract preparation, it is possible that this may be the source of the discrepancy (Baer and Johnson, 2000) . We did observe acquisition of C/EBPb-2 expression in the invasive mammary carcinoma samples we examined, which is noteworthy, given the ability of C/EBPb-2 expression to confer an invasive phenotype on MCF10A cells in culture. Interestingly, the role of C/EBPb in motility and invasion may represent an evolutionarily conserved function of C/EBPb prefigured by its Drosophila homologue, slow border (slbo). A variety of genetic screens (for review, see Montell, 2001 ) have demonstrated that conversion of border cells from a stationary group of epithelial cells to invasive cells during Drosophila oogenesis requires the activities of at least two transcriptional regulatory pathways, one of which is slbo.
Specific downstream targets of C/EBPb that would promote cellular transformation and invasion are not well characterized. However, we found that COX-2 expression is elevated in ecotopic-C/EBPb-2-, but not C/EBPb-1-expressing MCF10A cells. Since the COX-2 promoter contains a C/EBPb binding site and is known to be regulated by C/EBPb in some cell types, it is likely a direct target of C/EBPb-2 in transformed MCF10A cells. This result reinforces previous work performed by this laboratory and others that demonstrate C/EBPb-1 and -2 unique transactivating abilities (Eaton et al., 2001, Kowenz-Leutz and Leutz, 1999) . Whether the selective activation of COX-2 by C/EBPb-2 contributes to the transforming ability of this isoform of C/EBPb would require additional studies, such as employing cyclooxygenase inhibitors.
We have previously shown that C/EBPb-1 is located exclusively in the nucleus of normal mammary epithelial cells, whereas C/EBPb-2 is found in the cytoplasm as well as the nucleus in both normal and transformed cells (Eaton et al., 2001) . Tagged-C/EBPb-2 protein was also detected by indirect immunofluorescence in both the cytoplasm and nucleus of infected cells (Figure 2) . We do not yet know whether C/EBPb-2 in both subcellular compartments is necessary for the complete range of phenotypic changes, including loss of anchorage independence and invasive growth that have been observed in these cells. It is obvious that the nuclear form of C/EBPb-2 is directly or indirectly involved in changes in gene regulation that lead to anchorageindependent growth and expression of markers associated with having undergone EMT. However, it is possible that both nuclear and cytoplasmic C/EBPb-2 may be necessary for the oncogenic transformation of MCF10A cells in culture. We are addressing these issues by development of retroviral vectors carrying sitedirected mutants of C/EBPb-2 with a truncated leucine zipper that eliminates DNA binding or a mutated nuclear localization signal that disrupts nuclear import.
In our previous studies we found that seven of the 10 surgical primary breast tumor samples acquired elevated C/EBPb-2 (Eaton et al., 2001) . Since tissue samples are a heterogeneous mixture of cell types, it is difficult to compare the level of expression in primary tumors with that achieved upon retroviral transduction of MCF10A cells. MCF10A cells continue to express low, but detectable levels of C/EBPb-1, which presumably may compete with some C/EBPb-2, although the level of tagged-C/EBPb-2 in infected cells easily exceeds that of C/EBPb-1. It is not known if primary tumors continue to express C/EBPb-1, although all breast cancer cell lines that we have examined do not. However, C/EBPb is targeted by multiple kinases including those in both the Ras and PI3-kinase signalling pathways. It is likely that in primary breast tumors C/EBPb-2 expression may cooperate with altered signalling pathways to contribute to transformation and metastasis. Since these signalling pathways are not necessarily altered in the MCF10A cells, a much higher level of overexpression may be required to drive transformation by C/EBPb-2. Also, as mentioned above, not all of the ectopic C/EBPb-2 expressed in MCF10A cells is in the nucleus; approximately half remains cytoplasmic (although there is great cell-to-cell variability), where it is not able to orchestrate changes in gene expression.
Although the outcome of our work and others strongly suggests that C/EBPb-1 and -2 mediate distinct cellular functions, there is currently no information on the possible mechanism(s) by which C/EBPb-1 and -2 are selectively expressed (Kowenz-Leutz and Leutz, 1999; Eaton et al., 2001) . This is partly because the expression of C/EBPb-1 is generally absent from tissue culture cell lines, leading many to conclude that it is not expressed. Expression in normal tissue has only recently been documented (Eaton et al., 2001) . As is the case with the smallest C/EBPb isoform, C/EBPb-3 or LIP, mechanisms involving both alternative translation initiation and proteolytic clipping may occur depending on the cell type and circumstances involved (Calkhoven et al., 2000; Xiong et al., 2001; Baer and Johnson, 2000) . However, given the potential role that C/EBPb-2 may play in the genesis of metastatic breast cancer, it would be very valuable to begin to address the mechanism(s) of selective expression in normal and transformed mammary epithelial cells. Moreover, the development of transgenic and knock-in mouse models of C/EBPb-2 expression will be necessary to further define the role of C/EBPb-2 in the development of malignancies from skin to mammary gland. 
Materials and methods

Reagents
Cell lines
The previously characterized MCF10A human mammary cell line Tait et al., 1990) was obtained from the American Type Culture Collection (ATCC). Cells were grown in a 1 : 1(v/v) mixture of Ham's F12 and Dulbecco's modified Eagle medium (DMEM) containing 2.5 mm l-glutamine and supplemented with 5% equine serum, 10 mg/ml bovine insulin, 0.5 mg/ml hydrocortisone, 20 ng/ml epidermal growth factor, 100 ng/ml cholera toxin (Calbiochem Novabiochem, San Diego, CA, USA), 50 mg/ml gentamicin, 100 U/ml penicillin, and 100 mg/ml streptomycin (Life Technologies, Inc.). All the MCF10A subcultures generated by retroviral infection were propagated in the growth media described above. The human breast cancer cell line MDA-MB-231 (a gift of Dr Carlos Arteaga, Vanderbilt University) was maintained in Iscove's modified Eagle media supplemented with 10% fetal bovine serum (FBS) from HyClone Laboratories (Logan, UT, USA), 10 mg/ml bovine insulin, 50 mg/ml gentamicin, 100 U/ml penicillin, and 100 mg/ml streptomycin (Life Technologies, Inc.). The phoenix-ampho packaging cell line was obtained from the ATCC with the permission of GP Nolan (Stanford University, Palo Alto, CA, USA) and has been described previously (Grignani et al., 1998) . The packaging cells were maintained in DMEM supplemented with 10% heat-inactivated FBS (HyClone Laboratories, Inc.), 1 mm sodium pyruvate, 2 mm l-glutamine, 100 U penicillin, and 100 mg/ml streptomycin (Life Technologies, Inc.). All cells were grown at 371C in a humidified atmosphere containing 5% CO 2 , unless otherwise noted.
Cloning of recombinant retroviral constructs and virus preparation
The T7-tagged C/EBPb-2 recombinant retroviral constructs were derived from the previously described pRSETA-p35-C/EBPb prokaryotic expression vector (Hanlon et al., 2000) . The C/EBPb-2 coding sequences were excised from pRSETAp35-C/EBPb at the BamHI and EcoRI restriction sites, and inserted into the similarly digested eukaryotic expression vector pcDNA3.1HisC (Invitrogen Life Technologies, San Diego, CA, USA). The resulting plasmid, pcDNA3.1His-C/EBPb-2, was constructed such that the T7-tag leader sequences were fused in-frame at the N-terminus to rat C/EBPb coding sequences beginning at the second in-frame methionine. The pLZRS-His-C/EBPb-2 construct was generated by replacing the b-galactosidase (LacZ) coding sequence present in the previously described hybrid EBV/retroviral construct, pLZRS-LacZ (Kinsella and Nolan, 1996) , with the 1.1 kb T7-tagged C/EBPb-2 coding fragment from pcDNA3.1-His-C/EBPb-2 at the HinDIII and NotI restriction sites. The pLZRS-IRES-GFP construct was generated by replacing the LacZ coding sequences of pLZRS-LacZ with the 1346 bp internal ribosome entry site (IRES) and enhanced GFP coding sequences excised from pIRES2-EGFP expression vector (Clontech, Palo Alto, CA, USA) at the EcoRI and NotI restriction sites. The bicistronic pLZRS-His-C/EBPb-2-IRES-GFP construct was generated in a multistep protocol. First, the T7-tagged C/EBPb-2 sequences were subcloned into pIRES2-EGFP. This was accomplished by digesting pLZRSHis-C/EBPb-2 with EcoRI and BglII, and ligating the resulting 1430 bp fragment into pIRES2-EGFP at the EcoRI and BamHI restriction sites. The compatible sticky ends generated by the restriction enzymes BglII and BamHI allowed for ligation; however, neither site was regenerated in the resulting intermediate subclone, pHis-C/EBPb2-IRES-GFP. The bicistronic pLZRS-His-C/EBPb2-IRES-GFP construct was then generated by replacing LacZ coding sequences of pLZRSLacZ with the 2.5 kb His-C/EBPb2-IRES-GFP coding sequences from pHis-C/EBPb2-IRES-GFP vector at the EcoRI and NotI restriction sites.
Recombinant, amphotropic retroviral stocks were generated by transfecting the phoenix-ampho packaging cells independently with each of the above-described LZRS-based constructs, using calcium-phosphate DNA-precipitation methods described previously (Kinsella and Nolan, 1996) , with the following modifications. At 24 h prior to harvest, cultures were maintained at 321C and 5% CO 2 . At harvest, conditioned medium was collected, cell debris pelleted by centrifugation at 500 Â g for 5 min at room temperature (RT), and viruscontaining supernatant was aliquoted and stored at À701C.
Retroviral infections were carried out as follows: viral stocks were thawed in a 371C waterbath and immediately overlaid onto subconfluent MCF10A cells in the presence of 8 mg/ml polybrene. Cells were incubated for 3-5 h followed by the addition of an equal volume of growth media, resulting in a final polybrene concentration of 4 mg/ml. After an additional 18-20 h of incubation, the virus-polybrene-containing media was replaced with fresh growth media and the cells were maintained as described above. Infections were typically carried out at multiplicity of infections (MOIs) ranging from 50 to 200.
If fed fresh media every 3 days, a subpopulation of viable, nonadherent cells began to accumulate in the MCF10A cultures treated with tagged-C/EBPb-2 recombinant virus 4-5 days postinfection. Subcultures were established by pelleting the floating cells contained in the conditioned media by centrifugation at 500 Â g for 5 min at RT. After aspirating the media, the cells were gently resuspended in fresh growth media and added to a new culture dish. Numerous, floating subcultures were established from independent infections with either LZRS-His-C/EBPb-2-or LZRS-His-C/EBPb-2-IRES-GFP-derived retroviral stocks.
Immunoblot analysis
Whole cell extracts were prepared from 100 mm dishes of 80-90% confluent MCF10A by scraping into a chilled solution containing protease and phosphatase inhibitors, as described previously (Eaton et al., 2001) . Relative protein concentrations were determined using Protein Assay Reagent (BioRad Laboratories, Hercules, CA, USA) as per the manufacturer's instructions. Equivalent amounts of protein were loaded onto an 8% (Figures 2d and 9a) or a 10% SDS -PAGE (Figure 9b ) and separated by electrophoresis. The proteins were transferred to an Immobilon P filter and the blots were processed as described previously (Eaton et al., 2001) . After the nonspecific binding sites were blocked, the blots were incubated with primary Ab (C/EBPb at a 1 : 5000 dilution, Figure 2d ; COX-2 at a 1 : 8000 dilution. Figure 9a ; or T7-tag at a 1 : 20000 dilution, Figure 9b ) in TBS-T (100 mm Tris pH 7.5, 150 mm NaCl, and 0.05% Tween-20) containing 0.5% nonfat dried milk (NFDM) for 1 h at RT with gentle agitation. The blots were washed with three successive changes of TBS-T containing 0.5% NFDM at RT for 20 min and incubated with an HRP-conjugated goat anti-rabbit (Figures 2d and 9a) or an HRP-conjugated goat anti-mouse Ab (Figure 9b ) at a 1: 5000 dilution as described above for an additional hour. The blots were then washed with three successive changes of TBS-T solution for 15 min and signal was detected by chemiluminescence using SuperSignal West Pico reagent (Pierce, Rockford, IL, USA) and autoradiography with Kodak X-OMAT film (Rochester, NY, USA).
Colony formation in soft agar
Cells (1 Â 10 5 cells) were resuspended in 7 ml of 0.3% Difco's bactoagar (Detroit, MI, USA) and fully supplemented growth media (described above). This suspension was layered over 5 ml of a 0.7% agar-medium base in 60 mm dishes. Fresh top agar was overlaid weekly. After 20 days in culture, the colonies (>20 cells) were counted using a grid on the bottom of the dish and a microscope.
Indirect immunostaining and image acquisition
All cell cultures were grown in 35 mm dishes fitted with polylysine-coated glass coverslips (MatTek Corp, Ashland, MA, USA). To detect epitope-tagged C/EBPb-2, cultures were grown to 75-90% confluence, washed three times in PBS, fixed in 3.7% formalin in phosphate buffered saline (PBS) for 10 min at RT, washed an additional three times, and processed for indirect immunofluorescence. The cells were washed at least three times in PBS after each treatment. First, the cells were permeabilized in PBS containing 0.1% Triton X-100 for 20 min at RT. The cells were washed and nonspecific binding sites were blocked in PBS containing 5% BSA (Fraction V, Sigma) at 41C for 18-20 h in a humidified chamber. Immediately following aspiration of the blocking solution, the cells were incubated with anti-T7 tag monoclonal antibody at a dilution of 1 : 20000 in PBS containing 2% BSA and 0.1% Triton X-100 for 1 h at RT. The cells were washed as described above, except that the PBS contained 0.1% Triton X-100, then incubated for an additional hour at RT in the dark with fluorescent-conjugated Alexa 488 goat-anti-mouse secondary Ab diluted to a final concentration of 2 mg/ml in PBS containing 2% BSA and 0.1% Triton X-100. The cells were then washed five times in PBS containing 0.1% Triton X-100. Lastly, the cells were incubated with BO-PRO-3, a nuclearspecific fluorescent dye, according to the manufacturer's instructions, rinsed with double-distilled water (ddH 2 O), mounted, and visualized on a Zeiss LSM 410 confocal laser scanning inverted microscope. To detect E-cadherin expression, cells were grown to confluence, fixed in 4% paraformaldehye in PBS, and processed for indirect immunofluorescence as described above with the following exceptions. Nonspecific sites were blocked by incubating the cells in a humidified chamber 18-24 h at 41C in PBS containing 5% NFDM. Cells were incubated in the presence of primary anti-E-cadherin Ab diluted 1 : 200 in PBS containing 0.1% Triton X-100 and 2% NFDM for 1 h at RT, and washed. The cells were then incubated with Cy3-conjugated donkey anti-rabbit secondary Ab diluted 1 : 1000 in PBS containing 0.1% Triton X-100 and 2% NFDM. The cells were visualized by epifluorescent microscopy on a Zeiss Axiophot upright fluorescence microscope equipped with a Princeton Instruments Low-Light CCD camera. F-actin was detected by staining confluent cultures with fluorescent-conjugated Alexa 594 phalloidin according to the manufacturer's directions. Stained cells were mounted in Cytoseal XYL (Stephens Scientific; Kalamazoo, MI, USA) and visualized by epifluorescence as described above. Vimentin expression was detected by indirect immunofluorescence as described previously (Lochter et al., 1997b) , with the following exceptions. Confluent cells were grown on MatTek dishes, and the fluorescent-conjugated Alexa 546 goat anti-mouse secondary Ab was used at a final concentration of 2 mg/ml to indirectly detect vimentin expression. Cells were mounted in Aqua Poly/Mount and visualized by epifluorescence as described above.
Chemoinvasion assays
In vitro invasion assays were performed using 24-well Matrigel invasion chambers. Invasion through Matrigel-coated filters by untreated MCF10A cells, LZRS-IRES-GFP-infected MCF10A cells, and cells collected from three independently isolated C/EBPb-2-overexpressing MCF10A subcultures established via infection with either LZRS-His-C/EBPb-2 or LZRSHis-C/EBPb-2-IRES-GFP virus were compared. The human breast cancer cell line, MDA-MB-231, was included in each assay as an internal positive control. Cells were seeded at 2.5 Â 10 5 cells in the upper chamber of a 24-well transwell in the presence of 0.5% serum (FBS for MDA-MB-231s, horse for MCF10A-based cells). A chemoattractant gradient was established by placing fully supplemented growth media (described above) in the lower chamber. After 16-18 h of incubation, the cells on the upper surface of the filter were removed mechanically by wiping with a cotton swab. The cells that had migrated to the underside of the filter were fixed and stained with Diff-Quik stain set (Dade Behring Inc., Newark, DE, USA). Each filter was examined microscopically at Â 15 magnification, and the cells counted in four random fields were numerically averaged. Scores were normalized to the wellcharacterized, highly invasive MDA-MB -231 cell line that was included in each assay. The assays were performed in duplicate and repeated three times. The data were subject to statistical analysis using the analysis of variance (ANOVA) model with the Bonferroni adjustment.
